Sevabertinib in Advanced <i>HER2</i> -Mutant Non–Small-Cell Lung Cancer
Sevabertinib showed antitumor activity in patients with locally advanced or metastatic <i>HER2</i>-mutant NSCLC. Diarrhea was the most common adverse event. (Funded by Bayer; SOHO-01 ClinicalTrials.gov number, NCT05099172.).
Authors
- Jun Zhao (ORCID: https://orcid.org/0000-0001-9890-4582)
- Xiuning Le (ORCID: https://orcid.org/0000-0002-8554-1185)
- Nicoletta Brega (ORCID: https://orcid.org/0000-0002-5091-4631)
- Tine Descamps (ORCID: https://orcid.org/0000-0002-8874-2214)
- Jan C. Brase (ORCID: https://orcid.org/0000-0002-1325-2528)
- Paolo Grassi (ORCID: https://orcid.org/0000-0002-5691-2768)
- Herbert H. Loong (ORCID: https://orcid.org/0000-0002-6607-1106)
- Yuki Shinno
- Kōichi Goto (ORCID: https://orcid.org/0000-0002-3023-2510)
- Boon Cher Goh (ORCID: https://orcid.org/0000-0002-4107-102X)
- Dominik Rüttinger
- Hye Ryun Kim (ORCID: https://orcid.org/0000-0002-1842-9070)
- Pasi Antero Janne (ORCID: https://orcid.org/0000-0002-7821-4928)
- Liyun Miao (ORCID: https://orcid.org/0000-0001-9586-3244)
- Xiaorong Dong (ORCID: https://orcid.org/0000-0001-7470-1836)
- Gennaro Daniele (ORCID: https://orcid.org/0000-0001-5360-1895)
- Lin Wu (ORCID: https://orcid.org/0000-0001-7078-7767)
- Weichao Bao (ORCID: https://orcid.org/0000-0001-8459-0594)
- Nicolas M Girard (ORCID: https://orcid.org/0000-0001-9909-2299)
- Lin Li (ORCID: https://orcid.org/0009-0003-4709-7196)
- Rui Li (ORCID: https://orcid.org/0000-0002-5716-9259)
- Tae Min Kim (ORCID: https://orcid.org/0000-0001-6145-4426)
- Tsung‐Ying Yang
- G. Ruiter
- Silvia Novello
- Daniel Shao-Weng Tan (ORCID: https://orcid.org/0009-0005-4021-2176)
- Arsela Prelaj
- Shun Lu
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Central South University (CN)
- Bayer (United States) (US)
- National University of Singapore (SG)
- Chinese University of Hong Kong (HK)
- Yonsei University (KR)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Sir Run Run Shaw Hospital (CN)
- Agostino Gemelli University Polyclinic (IT)
- Shanghai Chest Hospital (CN)
- Seoul National University Hospital (KR)
- Taichung Veterans General Hospital (TW)
- National University Cancer Institute, Singapore (SG)
- Nanjing Drum Tower Hospital (CN)
- Oncode Institute (NL)
- Hunan Cancer Hospital (CN)
- Dana-Farber Cancer Institute (US)
- Bayer (Switzerland) (CH)
- Beijing Hospital (CN)
- Bayer (Italy) (IT)
- Wuhan Union Hospital (CN)
- National Cancer Centre Singapore (SG)
- National Cancer Center Hospital East (JP)
- Ministry of Education (ET)
- Ospedale San Luigi Gonzaga (IT)
- Tokyo National Hospital (JP)
- Fondazione IRCCS Istituto Nazionale dei Tumori (IT)
- Yonsei University Health System (KR)
- Beijing Obstetrics and Gynecology Hospital (CN)
- Bayer (United Kingdom) (GB)
- Bayer (Germany) (DE)
- Zhejiang University (CN)
- Institut Curie (FR)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-10-17
- DOI
- https://doi.org/10.1056/nejmoa2511065
- Citations
- 16
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 24.29